Products & Services · Maximum funding

ALN-AGT Phase 2 Clinical Trial — Maximum funding

Alnylam Pharmaceuticals ALN-AGT Phase 2 Clinical Trial — Maximum funding remained flat by 0.0% to $26.00M in Q1 2026 compared to the prior quarter.

Analysis

StatementSegment
First reportedQ3 2020
Last reportedQ1 2026
Metric ID: alny_segment_aln_agt_phase_2_clinical_trial_maximum_funding

Historical Data

2 periods
 Q4 '25Q1 '26
Value$26.00M$26.00M
QoQ Change—+0.0%
Range$26.00M – $26.00M

Frequently Asked Questions

What is Alnylam Pharmaceuticals's aln-agt phase 2 clinical trial — maximum funding?
Alnylam Pharmaceuticals (ALNY) reported aln-agt phase 2 clinical trial — maximum funding of $26.00M in Q1 2026.